2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Review slidesets and expert analyses of key data from the 2022 Clinical Oncology Annual Scientific Meeting!

Skin Cancer

Capsule Summary Slidesets

In this updated analysis of patients with PD-/PD-L1–treated metastatic cutaneous melanoma, tebentafusp, a bispecific therapy targeting gp100 and CD3, plus anti–PD-L1 was associated with a promising 1-year OS rate of 75%.

Released: June 13, 2022

PRADO confirmed high pathologic response rates with neoadjuvant ipilimumab + nivolumab in stage III melanoma and demonstrated good outcomes in patients with major pathologic responses not receiving therapeutic lymph node dissection and adjuvant therapy

Released: June 13, 2022

In patients with locally advanced desmoplastic melanoma, neoadjuvant pembrolizumab was associated with a pathologic CR rate of 55% and led to no toxicity-related surgery cancellations.

Released: June 10, 2022

Concurrent neoadjuvant dabrafenib and trametinib and pembrolizumab resulted in high pathologic response rate in patients with stage III melanoma, although with increased toxicity compared with sequential regimen or pembrolizumab monotherapy.

Released: June 9, 2022

Relatlimab + nivolumab was favored over nivolumab alone across key subgroups for PFS, OS, and ORR in previously untreated patients with advanced melanoma.

Released: June 9, 2022

A triplet combination of camrelizumab (anti–PD-1), apatinib (VEGFR-2–targeted TKI), and temozolomide showed promising antitumor activity and manageable toxicity in previously untreated advanced acral melanoma.

Released: June 13, 2022

In the phase I AMBER trial, the anti–TIM-3 mAb cobolimab combined with dostarlimab showed a manageable safety profile in patients with advanced solid tumors and preliminary antitumor activity in patients with advanced melanoma.

Released: June 20, 2022

The combination of atezolizumab, cobimetinib, and vemurafenib showed promising intracranial activity in advanced BRAFV600-mutated melanoma with CNS metastases.

Released: June 15, 2022

With 7.5-year follow-up, the phase III CheckMate 067 trial continued to demonstrate durable survival benefits with first-line nivolumab + ipilimumab in patients with advanced melanoma.

Released: June 16, 2022

Results through 27.4 months of follow-up continue to support the benefit of adjuvant pembrolizumab in reducing the risk of recurrence and distant metastasis in patients with stage IIB/IIC melanoma.

Released: June 10, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings